Q-omics provides the consensus-scored H2AC18 profile across patient tissues and cancer cell-line models. H2AC18 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, H2AC18 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, H2AC18 RNA expression shows 11,903 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight UVM, HNSC, and LUAD as cancer lineages where H2AC18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H2AC18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H2AC18 survival associations across molecular data types. H2AC18 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H2AC18 RNA expression–survival associations across cancer types. High H2AC18 expression shows unfavorable associations in UVM, DLBC, KIRP, THCA, CESC and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for H2AC18 RNA expression.
This table summarizes H2AC18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for H2AC18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H2AC18 shows higher tumor expression in HNSC, BRCA, KIRC, STAD, LIHC and ESCA. The HNSC box plot shows higher H2AC18 RNA expression in tumor versus normal tissue (log2 FC = +0.107, t-test p < 0.001).
This table shows molecular features associated with H2AC18 in patient tissues and cancer cell lines. In patient samples, H2AC18 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, H2AC18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT.
